First-generation approaches to intracellular biologics, such as cell-penetrating peptides
, have not realized their full potential due to limited uptake of larger macromolecules into cells and limited tolerability.
Academic partners have unique knowledge and technologies on supercharged viral proteins-derived cell-penetrating peptides
(eg from Dengue virus) and ultra-resistant cyclic peptides that may be transferred to the industrial partners, which in turn have specialized proprietary technologies on anticancer and/or peptide drugs technologies.
are often investigated as drug delivery vectors and are able to cross the cell membrane, although the exact mechanism for this is unknown.